Brentuximab vedotin for the treatment of Hodgkin’s lymphoma

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014;CA Cancer J Clin. 2014;64(1):9-29
   Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019-32
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology (ASCO). The Top 5 Advances in Modern Oncology. 2014. Available from: http://cancerprogress.net/top-5-advances-modern-oncology [cited 2015 Jan 26]
   Google Scholar
• Quddus F, Armitage JO. Salvage therapy for Hodgkin’s lymphoma. Cancer J 2009;15(2):161-3
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004;22(14):2835-41
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27(27):4548-54
   PubMed Web of Science ®Google Scholar
• Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363(7):653-62
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993;341(8852):1051-4
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359(9323):2065-71
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant 2003;32(7):673-9
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97(2):310-17
   PubMed Web of Science ®Google Scholar
• Younes A, Kadin ME. Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy. J Clin Oncol 2003;21(18):3526-34
   PubMed Web of Science ®Google Scholar
• Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997;272(4):2042-5
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146(2):171-9
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111(4):1848-54
   PubMed Web of Science ®Google Scholar
• Newland AM, Li JX, Wasco LE, et al. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy 2013;33(1):93-104
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812-21
   PubMed Web of Science ®Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125(8):1236-43
   PubMed Web of Science ®Google Scholar
• de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18(21):5845-9
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21(7):778-84
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs 2012;4(4):458-65
   PubMed Web of Science ®Google Scholar
• . Fanale MA, Forero-Torres A, Rosenblatt JD, et al.A Phase I. Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res 2012;18(1):248-55
   PubMed Web of Science ®Google Scholar
• Brentuximab vedotin. Drugs R D 2011;11(1):85-95
   PubMedGoogle Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30(18):2183-9
   PubMed Web of Science ®Google Scholar
• Siddiqi T, Thomas SH, Chen R. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmgenomics Pers Med 2014;7:79-85
   PubMedGoogle Scholar
• Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 2012;53(11):2283-6
   PubMed Web of Science ®Google Scholar
• Gandhi MD, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood 2014;123(18):2895-7
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14(13):1348-56
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16(3):284-92
   PubMed Web of Science ®Google Scholar
• Akhtar S, Al-Sugair AS, Abouzied M, et al. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant 2013;48(12):1530-6
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer J, Martin P, et al. Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. in 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012;119(26):6379-81
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Tsai NC, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014;20(11):1864-8
   PubMed Web of Science ®Google Scholar
• Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120(3):560-8
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014;7:24
   PubMed Web of Science ®Google Scholar
• Phase 3 frontline therapy trial in patients with advanced classical Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01712490
   Google Scholar
• Millennium Pharmaceuticals, I. and I. Seattle Genetics. Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma. 2019
   Google Scholar
• Connors JM, Ansell S, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: long-term outcomes. in 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01569204
   Google Scholar
• Borchmann P, Eichenauer DA, Plütschow A, et al. Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II Study. In 55th American Society of Hematology Annual Meeting and Exposition; Nw Orleans, Louisiana; 2013
   Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30(18):2190-6
   PubMed Web of Science ®Google Scholar
• Kumar A, Yahalom J, Schoder H, et al. Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma. in 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• Zinzani PL, Luminari S, Merli F, et al. Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. in 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• Center, U.N.C.L.C.C. and I. Seattle Genetics. Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma. 2015
   Google Scholar
• Induction Chemo w/ABVD followed by brentuximab vedotin consolidation in newly diagnosed, non-bulky stage I/II Hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01578967
   Google Scholar
• Park SI, Richards KL, Olajide O, et al. A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma. in 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park) 2008;22(12):1369-79
   PubMed Web of Science ®Google Scholar
• Seattle Genetics, I. A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL). 2016
   Google Scholar
• Forero A, Holkova B, Sharman J, et al. Brentuximab vedotin monotherapy and in combination with dacarbazine in frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a Phase 2 Study. in 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• A study of brentuximab vedotin in adults age 60 and above with newly diagnosed Hodgkin lymphoma (HL). Available from: https://clinicaltrials.gov/ct2/show/NCT01716806
   Google Scholar
• Seattle Genetics, I. Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma. 2015
   Google Scholar
• LaCasce A, Bociek RG, Matous J, et al. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. in 56th American Society of Hematology Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118(19):5119-25
   PubMed Web of Science ®Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85(5):320-4
   PubMed Web of Science ®Google Scholar
• Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin’s lymphoma. Hematology Am Soc Hematol Educ Program 2010;2010:93-100
   Google Scholar